<DOC>
	<DOCNO>NCT00039052</DOCNO>
	<brief_summary>RATIONALE : Interleukin-4 PE38KDEL cytotoxin may able deliver cancer-killing substance directly solid tumor cell . PURPOSE : Phase I trial study effectiveness intravenous interleukin-4 PE38KDEL cytotoxin treat patient recurrent metastatic kidney cancer , non-small cell lung cancer , breast cancer respond previous treatment .</brief_summary>
	<brief_title>Intravenous Interleukin-4 PE38KDEL Cytotoxin Treating Patients With Recurrent Metastatic Kidney Cancer , Non-Small Cell Lung Cancer , Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose interleukin-4 PE38KDEL cytotoxin patient recurrent unresponsive , metastatic renal cell , non-small cell lung , breast cancer overexpresses interleukin-4 receptor . - Determine qualitative quantitative toxic effect drug , include duration intensity toxic effect , patient . - Determine pharmacokinetic behavior drug patient . - Determine antibody response ( ) patient treat drug . - Determine , preliminary manner , antitumor activity drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive interleukin-4 PE38KDEL cytotoxin ( NBI-3001 ) IV 10 minute daily day 1-5 . Treatment repeat every 28 day absence disease progression , unacceptable toxicity , detection neutralize antibody . Cohorts 3-6 patient receive escalate dos NBI-3001 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A maximum 36 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent unresponsive , metastatic renal cell , nonsmall cell lung , breast cancer treat previously standard surgery , radiotherapy , chemotherapy , immunotherapy available treatment option currently exist Confirmed overexpression interleukin4 receptor Measurable disease ( lesion great 10 mm CT scan ) OR Evaluable disease No prior concurrent clinically significant brain metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Transaminases great 1.5 time ULN Albumin least 2.5 g/dL Hepatitis B surface antigen negative Hepatitis C antibody negative No prior concurrent hepatic disease ( e.g. , hepatitis alcoholic liver disease ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : See Surgery Electrocardiogram normal MUGA scan normal No congestive heart failure No cardiac arrhythmia require treatment No myocardial infarction No clinical evidence coronary artery disease ( unless cardiac evaluation evidence adequate coronary function stress test angiography ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week , , least 3 month study No concurrent underlie medical condition would preclude study control No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics At least 1 year since prior surgery angioplasty coronary artery disease Other : At least 28 day since prior experimental drug recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>